Real World Clinical Experience of Biosimilar G-CSF (Grastofil) for Autologous Peripheral Blood Stem Cell Mobilization: Single Center Experience in Canada Following Early Adoption

Real World Clinical Experience of Biosimilar G-CSF (Grastofil) for Autologous Peripheral Blood Stem Cell Mobilization: Single Center Experience in Canada Following Early Adoption

<i>Introduction:</i> Granulocyte colony-stimulating factor (G-CSF) is the first line treatment for mobilization, most commonly using a regimen of daily filgrastim. The use of biosimilars can provide substantial cost savings to the health care system while delivering comparable efficacy o...

Full description

Bibliographic Details
Main Authors: Vibhuti Aggarwal, Waleed Sabry, Mohamed Elemary, Mark Bosch, Pat Danyluk, Prosanta Mondal, Julie Stakiw
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Current Oncology
Subjects:
Grastofil 1
Biosimilar 2
Stem Cell Mobilization 3
Online Access:https://www.mdpi.com/1718-7729/28/3/148

Internet

https://www.mdpi.com/1718-7729/28/3/148

Similar Items